TCDIFLU

Impact of adjuvants on T cell differentiation after Influenza Vaccination analyzed at the Single Cell Level

 Coordinatore GLAXOSMITHKLINE VACCINES SRL 

 Organization address address: Via Fiorentina 1
city: SIENA
postcode: 53100

contact info
Titolo: Dr.
Nome: Francesco
Cognome: Gulli
Email: send email
Telefono: +39 0577 243390

 Nazionalità Coordinatore Italy [IT]
 Totale costo 180˙084 €
 EC contributo 180˙084 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2010-IEF
 Funding Scheme MC-IEF
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-03-01   -   2013-02-28

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    GLAXOSMITHKLINE VACCINES SRL

 Organization address address: Via Fiorentina 1
city: SIENA
postcode: 53100

contact info
Titolo: Dr.
Nome: Francesco
Cognome: Gulli
Email: send email
Telefono: +39 0577 243390

IT (SIENA) coordinator 180˙084.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

adjuvants    cells    flu    subpopulations    seasonal    protection    differentiation    cell    clearance    vaccine    vaccines    immune    viral    populations    influenza    single    lymphocytes    vaccination    cd    infection   

 Obiettivo del progetto (Objective)

'Mutating viruses and resistance to drugs are the major challenges to overcome in influenza (flu) prevention and treatment. Virus-neutralizing antibodies are the key for protection against flu infection, but flu-specific CD4 and CD8 T cells play a significant role by providing help to B cells and in viral clearance, respectively. There are many vaccines against flu infection approved for human use. The generally effective seasonal vaccines, however, have a number of deficiencies, including the need to repeat the injections every year with a newly updated vaccine, which provides only antibody-dominated subtype-specific protection. Adjuvants are used to enhance the immune response to a vaccine. They lead to different types of cell-mediated immune responses. The T cell type (Th1, Th2, cytotoxic) and the magnitude of the immune response discriminate between viral clearance and immunopathology. Particular T cell subpopulations (like Th1 IFN-γ or CD8 perforin or Fas expressing cells) may be responsible for protection after infection or vaccination and may give correlation to protective adjuvants. Studies of T cells using assays analyzing entire cell populations are not suitable to uncover these cell populations. We propose a detailed T cell differentiation profiling of CD4 and CD8 T lymphocytes at the single cell level after flu vaccination using the quantitative single cell multiplex RT-PCR method. Individual T lymphocytes purified from the vaccination site draining lymph nodes will be analyzed for the presence of up to twenty important differentiation markers. The results will be verified by additional methods, like flow cytometry or confocal microscopy. This project will reveal the presence of T cell subpopulations possibly correlated to protection after flu infection with mouse-adapted PR8 influenza strain or immunization with seasonal flu vaccine, with special consideration on the effect of adjuvants.'

Introduzione (Teaser)

Understanding vaccine immunogenicity and mode of action at the single-cell level has important clinical implications for inducing immune protection. Based on this, European immunologists investigated the impact of different flu vaccination regimens on the activation status of immune cells.

Altri progetti dello stesso programma (FP7-PEOPLE)

AFRICANMIGRANTWOMEN (2012)

African Migrant Women

Read More  

MARINCOMP (2014)

Novel Composite Materials and Processes for Offshore Renewable Energy

Read More  

GRAND (2013)

GRAvitational N-body Dynamics: Dynamics and evolution of multiple planetary systems

Read More